Hypogammaglobulinemia and bacterial infections following pediatric post‐transplant lymphoproliferative disorder in the rituximab era

Abstract

While RTX is an effective treatment for PTLD, hypogammaglobulinemia can persist for up to 2 years following RTX therapy, which may be associated with the higher cumulative rates of CPBI observed in RTX-treated patients.